Document:

<PAGE>

                              MAGYAR BANCORP, INC.

                           CHANGE IN CONTROL AGREEMENT
                                       FOR

                            _______________________

        This AGREEMENT is made effective as of ______________ __, 2005 by and
between MAGYAR BANCORP, INC., a Delaware corporation with its principal place of
business at 400 Somerset Street, New Brunswick, New Jersey 08903 (the
"Company"), and _____________________ (the "Executive"). Any reference to "Bank"
herein shall mean Magyar Bank, a New Jersey chartered stock savings bank or any
successor thereto.

        WHEREAS, the Company recognizes the substantial contribution the
Executive has made to the Company and wishes to protect his position therewith
for the period provided in this Agreement; and

        WHEREAS, the Executive has been elected to, and has agreed to serve in
the position of _______________for the Company, a position of substantial
responsibility;

        NOW, THEREFORE, in consideration of the contribution of the Executive,
and upon the other terms and conditions hereinafter provided, the parties hereto
agree as follows:

1.      TERM OF AGREEMENT

        The "term" of this Agreement shall be twenty-four (24) full calendar
months from the effective date of this Agreement set forth above, and shall
include any extension or renewal made pursuant to this Section. Commencing on
_______________, 2006 and continuing on ___________ of each year thereafter (the
"Anniversary Date"), this Agreement shall renew for an additional year such that
the remaining term shall be two (2) years unless written notice of non-renewal
("Non-Renewal Notice") is provided to Executive at least thirty (30) days and
not more than sixty (60) days prior to any such Anniversary Date, that this
Agreement shall terminate at the end of twenty-four (24) months following such
Anniversary Date.

2.      PAYMENTS TO EXECUTIVE UPON CHANGE IN CONTROL

        This Agreement provides for certain payments and benefits to Executive
only in the event of Change in Control followed by a termination of Executive's
services as described in this Agreement.

        (a)     Upon the occurrence of a Change in Control of the Company or the
Bank (as herein defined) followed at any time during the term of this Agreement
by Executive's voluntary termination of employment in accordance with this
Section 2(a) or involuntary termination of the Executive's employment, other
than for Just Cause (as defined in Section 2(c) hereof), the provisions of
Section 3 shall apply. Upon the occurrence of a Change in Control, the Executive
shall have the right to elect to voluntarily terminate his employment at any
time during the term of this Agreement following a demotion, loss of title,
office or significant authority (in each case, other than as a result of the
fact that either the Bank or the Company is merged into another entity in
connection with the Change in Control and will not operate as a stand-alone,

<PAGE>

independent entity), a reduction in his annual compensation or benefits, or
relocation of his principal place of employment by more than 30 miles from its
location immediately prior to the Change in Control.

        (b)     A "Change in Control" of the Company or the Bank shall mean a
change in control of a nature that: (i) would be required to be reported in
response to Item 5.01 of the current report on Form 8-K, as in effect on the
date hereof, pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934 (the "Exchange Act"); or (ii) results in a Change in Control of the Company
or the Bank within the meaning of the Bank Holding Company Act, as amended, and
applicable rules and regulations promulgated thereunder (collectively, the
"BHCA") as in effect at the time of the Change in Control; or (iii) without
limitation such a Change in Control shall be deemed to have occurred at such
time as (a) any "person" (as the term is used in Sections 13(d) and 14(d) of the
Exchange Act) is or becomes the "beneficial owner" (as defined in Rule 13d-3
under the Exchange Act), directly or indirectly, of securities of the Bank
representing 25% or more of the combined voting power of Company's outstanding
securities, except for any securities purchased by the Bank's employee stock
ownership plan or trust; or (b) individuals who constitute the Board on the date
hereof (the "Incumbent Board") cease for any reason to constitute at least a
majority thereof, PROVIDED that any person becoming a director subsequent to the
date hereof whose election was approved by a vote of at least three-quarters of
the directors comprising the Incumbent Board, or whose nomination for election
by the Company's stockholders was approved by the same Nominating Committee
serving under an Incumbent Board, shall be, for purposes of this clause (b),
considered as though he were a member of the Incumbent Board; or (c) a plan of
reorganization, merger, consolidation, sale of all or substantially all the
assets of the Company or the Bank or similar transaction in which the Company or
Bank is not the surviving institution occurs; or (d) a proxy statement
soliciting proxies from stockholders of the Company, by someone other than the
current management of the Company, seeking stockholder approval of a plan of
reorganization, merger or consolidation of the Company or similar transaction
with one or more corporations as a result of which the outstanding shares of the
class of securities then subject to the plan are exchanged for or converted into
cash or property or securities not issued by the Company; or (e) a tender offer
is made for 25% or more of the voting securities of the Company and the
shareholders owning beneficially or of record 25% or more of the outstanding
securities of the Company have tendered or offered to sell their shares pursuant
to such tender offer and such tendered shares have been accepted by the tender
offeror. Notwithstanding anything in this subsection to the contrary, a Change
in Control shall not be deemed to have occurred upon the conversion of the
Company's mutual holding company parent to stock form, or in connection with any
reorganization used to effect such a conversion.

        (c)     Even if a Change in Control shall occur, the Executive shall not
have the right to receive termination benefits pursuant to Section 3 hereof upon
termination for Just Cause. The phrase "Just Cause" as used herein, shall exist
when there has been a good faith determination by the Board that there shall
have occurred one or more of the following events with respect to the Executive:
(i) the conviction of the Executive of a felony or of any lesser criminal
offense involving moral turpitude; (ii) the willful commission by the Executive
of a criminal or other act that, in the judgment of the Board will likely cause
substantial economic damage to the Company or the Bank or substantial injury to
the business reputation of the Company or Bank; (iii) the commission by the
Executive of an act of fraud in the performance of his duties on behalf of the

                                       2
<PAGE>

Company or Bank; (iv) the continuing willful failure of the Executive to perform
his duties to the Company or Bank (other than any such failure resulting from
the Executive's incapacity due to physical or mental illness) after written
notice thereof (specifying the particulars thereof in reasonable detail) and a
reasonable opportunity to be heard and cure such failure are given to the
Executive by the Board; or (v) an order of a federal or state regulatory agency
or a court of competent jurisdiction requiring the termination of the
Executive's employment by the Company. Notwithstanding the foregoing, Just Cause
shall not be deemed to exist unless there shall have been delivered to the
Executive a copy of a resolution duly adopted by the affirmative vote of not
less than a majority of the entire membership of the Board at a meeting of the
Board called and held for the purpose (after reasonable notice to the Executive
and an opportunity for the Executive to be heard before the Board), finding that
in the good faith opinion of the Board the Executive was guilty of conduct
described above and specifying the particulars thereof. Prior to holding a
meeting at which the Board is to make a final determination whether Just Cause
exists, if the Board determines in good faith at a meeting of the Board, by not
less than a majority of its entire membership, that there is probable cause for
it to find that the Executive was guilty of conduct constituting Just Cause as
described above, the Board may suspend the Executive from his duties hereunder
for a reasonable period of time not to exceed fourteen (14) days pending a
further meeting at which the Executive shall be given the opportunity to be
heard before the Board. For purposes of this subparagraph, no act or failure to
act, on the Executive's part shall be considered "willful" unless done, or
omitted to be done, by him not in good faith without reasonable believe that his
action or omission was in the best interest of the Company and the Bank. Upon a
finding of Just Cause, the Board shall deliver to the Executive a Notice of
Termination, as more fully described in Section 4 below.

3.      TERMINATION

        (a)     Upon the occurrence of a Change in Control, followed at any time
during the term of this Agreement by the involuntary termination of the
Executive's employment other than due to termination for Just Cause, or
voluntary termination for one or more of the reasons set forth in Section 2(a)
hereof, the Company shall be obligated to pay the Executive, or in the event of
his subsequent death, his beneficiary or beneficiaries, or his estate, as the
case may be, as severance pay, a sum equal to two times the sum of (i) the
highest rate of base salary, and (ii) highest rate of bonus awarded to the
Executive during the prior three years, subject to applicable withholding taxes.

        (b)     Upon the occurrence of a Change in Control of the Company
followed at any time during the term of this Agreement by the Executive's
involuntary termination of employment other than for termination for Just Cause,
or voluntary termination for one or more of the reasons set forth in Section
2(a) hereof, the Company shall cause to be continued at no cost to Executive,
life, medical and dental coverage substantially identical to the coverage
maintained by the Company for the Executive prior to his severance. Such
coverage and payments shall cease upon expiration of twenty-four months.

        (c)     Upon the occurrence of a Change in Control, the Executive will
have such rights as specified in any other employee benefit plan with respect to
options and such other rights as may have been granted to the Executive under
such plans.

                                       3
<PAGE>

        (d)     Any cash severance payments shall be made in a lump sum within
thirty (30) days (or, in the event Section 409A of the Code is applicable, on
the first day of the seventh full month) of Executive's termination of
employment. Such payments shall not be reduced in the event the Executive
obtains other employment following termination of employment with the Company.

        (e)     Notwithstanding the preceding paragraphs of this Section 3, in
no event shall the aggregate payments or benefits to be made or afforded to the
Executive under said paragraphs (the "Termination Benefits") constitute an
"excess parachute payment" under Section 280G of the Code or any successor
thereto, and in order to avoid such a result, Termination Benefits will be
reduced, if necessary, to an amount (the "Non-Triggering Amount"), the value of
which is one dollar ($1.00) less than an amount equal to three (3) times the
Executive's "base amount", as determined in accordance with said Section 280G.
The allocation of the reduction required hereby among Termination Benefits
provided by the preceding paragraphs of this Section 3 shall be determined by
the Executive.

4.      NOTICE OF TERMINATION

        Any purported termination by the Company or by the Executive shall be
communicated by Notice of Termination to the other party hereto. For purposes of
this Agreement, a "Notice of Termination" shall mean a written notice which
shall indicate the Date of Termination and, in the event of termination by the
Executive, the specific termination provision in this Agreement relied upon and
shall set forth in reasonable detail the facts and circumstances claimed to
provide a basis for termination of the Executive's employment under the
provision so indicated. "Date of Termination" shall mean the date specified in
the Notice of Termination (which, in the case of a termination for Just Cause,
shall be immediate). In no event shall the Date of Termination exceed 30 days
from the date Notice of Termination is given.

5.      SOURCE OF PAYMENTS

        It is intended by the parties hereto that all payments provided in this
Agreement shall be paid in cash or check from the general funds of the Company,
provided, however, that in the event that the payment of any amounts due under
Section 3 above is made by the Bank, such payment shall offset the payment due
from the Company hereunder.

6.      EFFECT ON PRIOR AGREEMENTS AND EXISTING BENEFIT PLANS

        This Agreement contains the entire understanding between the parties
hereto and supersedes any prior agreement between the Company and the Executive,
except that this Agreement shall not affect or operate to reduce any benefit or
compensation inuring to the Executive of a kind elsewhere provided. No provision
of this Agreement shall be interpreted to mean that the Executive is subject to
receiving fewer benefits than those available to him without reference to this
Agreement.

7.      NO ATTACHMENT

        (a)     Except as required by law, no right to receive payments under
this Agreement shall be subject to anticipation, commutation, alienation, sale,
assignment, encumbrance, charge,

                                       4
<PAGE>

pledge, or hypothecation, or to execution, attachment, levy, or similar process
or assignment by operation of law, and any attempt, voluntary or involuntary, to
effect any such action shall be null, void, and of no effect.

        (b)     This Agreement shall be binding upon, and inure to the benefit
of, the Executive, the Company and their respective successors and assigns.

8.      MODIFICATION AND WAIVER

        (a)     This Agreement may not be modified or amended except by an
instrument in writing signed by the parties hereto.

        (b)     No term or condition of this Agreement shall be deemed to have
been waived, nor shall there be any estoppel against the enforcement of any
provision of this Agreement, except by written instrument of the party charged
with such waiver or estoppel. No such written waiver shall be deemed a
continuing waiver unless specifically stated therein, and each such waiver shall
operate only as to the specific term or condition waived and shall not
constitute a waiver of such term or condition for the future or as to any act
other than that specifically waived.

9.      REQUIRED PROVISIONS

        Notwithstanding anything herein contained to the contrary, any payments
to Executive by the Company, whether pursuant to this Agreement or otherwise,
are subject to and conditioned upon their compliance with Section 18(k) of the
Federal Deposit Insurance Act, 12 U.S.C. Section 1828(k), and the regulations
promulgated thereunder in 12 C.F.R. Part 359.

10.     SEVERABILITY

        If, for any reason, any provision of this Agreement, or any part of any
provision, is held invalid, such invalidity shall not affect any other provision
of this Agreement or any part of such provision not held so invalid, and each
such other provision and part thereof shall to the full extent consistent with
law continue in full force and effect.

11.     HEADINGS FOR REFERENCE ONLY

        The headings of sections and paragraphs herein are included solely for
convenience of reference and shall not control the meaning or interpretation of
any of the provisions of this Agreement.

12.     GOVERNING LAW

        The validity, interpretation, performance, and enforcement of this
Agreement shall be governed by the laws of the State of Delaware.

        Any dispute or controversy arising under or in connection with this
Agreement shall be settled exclusively by arbitration, conducted before a panel
of three arbitrators sitting in a location selected by the employee within fifty
(50) miles from the location of the Association, in accordance with the rules of
the Judicial Mediation and Arbitration Systems (JAMS) then in

                                       5
<PAGE>

effect. Judgment may be entered on the arbitrator's award in any court having
jurisdiction; provided, however, that subject to Section 3(c) hereof, the
Executive shall be entitled to seek specific performance of his right to be paid
until the Date of Termination during the pendency of any dispute or controversy
arising under or in connection with this Agreement.

13.     PAYMENT OF LEGAL FEES

        All reasonable legal fees paid or incurred by the Executive pursuant to
any dispute or question of interpretation relating to this Agreement shall be
paid or reimbursed by the Company if the Executive is successful on the merits
pursuant to a legal judgment, arbitration or settlement.

14.     SUCCESSOR TO THE COMPANY

        The Company shall require any successor or assignee, whether direct or
indirect, by purchase, merger, consolidation or otherwise, to all or
substantially all the business or assets of the Company, expressly and
unconditionally to assume and agree to perform the Company's obligations under
this Agreement, in the same manner and to the same extent that the Company would
be required to perform if no such succession or assignment had taken place.

15.     OBLIGATIONS OF COMPANY

        The termination of Executive's employment, other than following a Change
in Control, shall not result in any obligation of the Company under this
Agreement.

                                       6
<PAGE>

16.     SIGNATURES

        IN WITNESS WHEREOF, the Company has caused this Agreement to be executed
by its duly authorized officer, and the Executive has signed this Agreement, on
the day and date first above written.

ATTEST:                                    MAGYAR BANCORP, INC.

________________________________           By:__________________________________
                                              President

WITNESS:                                   EXECUTIVE

________________________________           By:__________________________________

                                       7Purchase Agreement dated August 12, 2005

 Exhibit 10.1 
  
 ANDA SALE AND ASSIGNMENT AGREEMENT FOR ANDA’s listed on Exhibit “A” dated as of August 12, 2005 (this
“Agreement”), by and between AMERICAN ANTIBIOTICS, LLC., a Florida Limited Liability Company formed by GEOPHARMA, INC. having its principal place of business at 6950 Bryan Dairy Road, Largo, Florida 33777 (“Buyer”),
and CONSOLIDATED PHARMACEUTICAL GROUP, INC., a corporation organized under the laws of Maryland having its principal place of business at 6110 Robinwood Road, Baltimore, Maryland 21225 (“Seller”). 
  
 BACKGROUND 
  
 Seller desires to sell, transfer and assign to Buyer, and Buyer desires to
purchase and acquire from Seller, all of Seller’s right, title and interest to its ANDAs and certain equipment, as is as outlined in Exhibit A and Exhibit B, all on the terms and subject to the conditions set forth herein. 
  
 In consideration of the mutual promises, covenants, representations,
warranties and agreements, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound, hereby covenant and agree as follows: 
  
 ARTICLE I 
  
 DEFINITIONS 
  
 The terms defined in this Article I, whenever used herein shall have the following meanings: 
  
 1.1 “Affiliate” shall mean any Person that directly or
indirectly controls, is controlled by or is under common control with another Person. A person or entity shall be deemed to control a corporation (or other entity) if such person or entity possesses, directly or indirectly, the power to direct or
cause the direction of the management and policies of such corporation (or other entity) whether through the ownership of voting securities, by contract or otherwise. 
  
 1.2 “Agreement” shall mean this agreement between Seller and Buyer. 
  
 1.3 “ANDA” shall mean an abbreviated new drug application
filed with the FDA covering a Product. 
  
 1.4
“Buyer” shall have the meaning set forth in the first paragraph of this Agreement. 
  
 1.5 “Buyer Claimant” shall have the meaning set forth in the Section 7.1 of this Agreement. 

 1.6 “Encumbrance” shall mean any lien, encumbrance, option, right of first refusal or
security interest of any kind whatsoever. 
  
 1.7
“Excluded Liabilities” shall have the meaning set forth in Section 2.1(b) of this Agreement. 
  
 1.8 “FDA” shall mean the United States Food and Drug Administration. 
  
 1.9 “Included Assets” shall mean all of Seller’s right, title and interest in, to and under all
Included Books and Records, Included Intellectual Property, Included Authorizations, including without limitation those assets identified on Exhibit A and Exhibit B hereto. 
  
 1.10 “Included Authorizations” shall mean Seller’s ANDA per Exhibit A all supplements and amendments
thereto, including all pending or in-process registrations, supplements and amendments related to the Products, including without limitation those documents identified on Exhibit A. 
  
 1.11 “Included Books and Records” shall mean copies, if any, only to the extent specifically related to the
Products, of all annual reports and adverse event reports related to the ANDAs, correspondence with the FDA, exception reports and investigations, specification for raw materials and FDA communication thereon, communication relating to packaging
with any of the FDA, vendors or suppliers, master batch records and batch records for released batches, samples (except that Seller shall be entitled to hold such representative portions of the samples as is required by law), stability and special
study data, analytical methods and validation, process validation and complaints files, new or improved manufacturing process documentation, validations documents, lab notebooks and technical data files (upon request for such notebooks and files by
Buyer) and field alert reports, related to the Products, including without limitation those books and records identified on Schedule 1.13 hereto. 
  
 1.12 “Included Intellectual Property” shall mean all know-how, information, including without limitation any scientific, pharmaceutical
or technical information, substances, techniques, processes, systems, designs, expertise, screens, models, methods, assays, screenings, patents, inventions (whether patented, patentable or not), discoveries, trade secrets, together with all
experience, data, formulas, procedures and results, and including all biological, chemical, pharmacological, toxicological, clinical, analytical, assay, quality control, and manufacturing data and technology and any improvements, modifications
and/or alternations made thereto, relating to the Products, including without limitation those identified on Exhibit A hereto. 

 1.13 “Indemnitee” and “Indemnitor” shall have the meanings set forth in
Section 7.3(a) of this Agreement. 
  
 1.14
“Leases” shall have the meaning set forth in Section 7.1 of this Agreement. 
  
 1.15 “Person” shall mean any natural person, corporation, limited or limited liability partnership, general partnership, joint venture,
association, joint-stock company, limited liability company, company, trust, bank, trust company, land trust, business trust or other organization whether or not a legal entity, and any governmental unit or agency or political subdivision thereof.

  
 1.16 “Equipment” means all equipment all
ready installed in the facilities, as is. 
  
 1.17
“Transfer Date” shall mean, with respect to each ANDA related to a Product, the date that the FDA accepts and records the transfer of the ANDA related to such Product by Seller to Buyer. 
  
 ARTICLE II 
  
 SALE AND PURCHASE OF THE INCLUDED ASSETS 
  
 2.1 Purchase of the Included Assets. 
  
 (a) Upon the terms and subjects to the conditions hereof,
and upon the basis of the agreements, representations and warranties contained in this Agreement, effective as of the date hereof, Seller hereby sells, transfers, assigns, conveys and delivers to Buyer, and Buyer hereby purchases and acquires from
Seller, all of the Included Assets, free and clear of Encumbrances. 
  
 2.2 Purchase Price. In consideration for the sale and assignments of the Included Assets outlined in Exhibit A and Exhibit B; Buyer shall pay to Seller a purchase price of $3,000,000 payable (I) $500,000 in cashier’s check
at the signing of this agreement and (II) $2,500,000 in a note, payable to the Seller (Seller’s Note) payable to the Buyer under the following terms: 
 (1) Terms: 3 years 
  
 (2) Three equal installments, with first installment due 12 months from the date of signing this letter. 
  
 (3) Interest 5% payable annually with the principle. 

 2.3 Notifications and Consents. Simultaneously herewith, the Seller is delivering to Seller
executed assignments of the ANDAs together with written notification to the FDA of the immediate transfer of rights to the ANDAs to Buyer. Buyer and Seller shall use all reasonable efforts to obtain all consents, approvals and waivers from, and give
all notices to, and make all declarations, filings and registrations with, any governmental and regulatory agencies that are required to consummate the transactions contemplated hereby. Buyer and Seller shall coordinate and cooperate with one
another and supply such commercially reasonable assistance as may be reasonably requested by each in connection with the foregoing. Until the Transfer Date, Seller shall maintain (at Seller’s sole cost and expense) all existing governmental
authorizations, including ANDAs with respect to the Products. Seller further, agrees that from the date hereof until such time as the ANDAs are transferred to Buyer, Seller shall make no amendments or supplements to the ANDAs without the prior
written consent of Buyer, not to be unreasonably withheld, and keep Buyer fully apprised of all matters relating to the maintenance of the ANDAs. 
  
 2.4 Adverse Events. Seller and Buyer each agree to notify the other within five (5) days of any serious and unexpected adverse reactions
reported to either of them resulting from the use of the Products (whether inside or outside of the Territory). Seller and Buyer shall each notify the other promptly of any other complains or adverse reactions from third parties reported to either
of them resulting from use of the Products sold under the Seller’s label. Buyer assumes the responsibility to notify FDA of any and all ADER after the term is completed. 
  
 2.5 Further Assistance. Seller shall provide, at Seller’s cost and expense, commercially reasonable assistance,
including without limitation, technology transfer assistance, requested by Buyer in connection with the coamoxyclav formulation and technology to Buyer. 
  
 ARTICLE III 
  
 REPRESENTATIONS AND WARRANTIES OF SELLER 
  
 Seller hereby represents and warrants to Buyer as follows: 
  
 3.1 Organization. Seller is a corporation duly organized, under the laws of the jurisdiction in which it was formed, with full corporate power and
authority to own, lease and operate its properties and assets and to conduct its business as it is now being conducted. 
  
 3.2 Authority. Seller has all requisite power and authority to execute and deliver this Agreement and to perform, carry out and consummate the
transactions contemplated hereby. The execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of Seller. This Agreement constitutes 

 
the legal, valid and binding obligation of Seller, enforceable against Seller in accordance with its terms. 
  
 3.3 No Breach. Neither the execution and delivery of this Agreement by
Seller nor the consummation of the transactions contemplated hereby will: (a) result in the creation of, or give any party the right to create, any Encumbrance upon the Included Assets; (b) to its knowledge, conflict with, violate, result
in breach of or constitute a default under any judgment, decree, order or process of any court or governmental authority applicable to Seller. 
  
 3.4 Assets. 
  
 (a) Seller has good and freely transferable title to Included Asset per Exhibit A & Exhibit B, free and clear of all Encumbrances,
and, has the complete and unrestricted power and right to sell and transfer the Included Assets to Buyer in accordance with the terms hereof. 
  
 (b) The Included Assets represent all of Seller’s contracts, licenses, permits, approvals, authorizations, registrations, rights to
registrations, pending or in-process registrations and qualifications (including the ANDAs and supplements and amendments thereto), issued by any federal, state, local or governmental authority, United States and foreign patents and pending patent
applications, unpatented inventions, trademarks, service marks, trade names, know-how, formulae and manufacturing technology, and Included Books and Records, of or for the Products, other than the Excluded Assets. 
  
 (c) Seller has not transferred, sold, assigned, licensed or
given any rights, title or interest to the Included Assets to any third party in the territory. 
  
 3.5 Litigation. There is presently no litigation pending or to its best knowledge threatened against Seller, relating to any of the Products or the
Included Assets. 
  
 3.6 No Breach. Neither the execution
and delivery of this Agreement by Seller nor the consummation of the transactions contemplated herein will: (i) violate any provision of the organizational documents of Seller; (ii) conflict with, result in a breach of or constitute a
default (or an event which, with or without notice, lapse of time or both, would constitute a default) under, or give any third party the right to terminate or modify, any material agreement or other instrument to which Seller is a party or by
Seller or any of its assets are subject or bound; (iii) conflict with, violate, result in a breach of or constitute a default under any judgment, decree, order or process of any court or governmental authority applicable to Seller;
(iv) conflict with or violate any material statute, law or regulation applicable to Seller’s business; and (v) no event has occurred or with the passage of time or the giving of notice will occur which would prevent Seller from
obtaining any authorization, consent, approval or waives from any federal or state governmental or regulatory authority required in connection with the manufacture, distribution, export or sale of the Products in or to the Territory. 

 3.7 Regulatory Matters. 
  
 (a) No individual involved in the preparation or submission of any ANDA or, supplement or amendment for either product, or
in the generation of data utilized in any such submission, has been debarred, or is subject to debarment, by any U.S. federal agency. 
  
 ARTICLE IV 
  
 REPRESENTATION AND WARRANTIES OF BUYER 
  
 Buyer hereby represents and warrants to Seller as follows: 
  
 4.1 Organization and Qualification. Buyer is a corporation duly organized, under the laws of the jurisdiction in which it was formed, with full
corporate power and authority to own, lease and operate its properties and assets and to conduct its business as it is now being conducted. 
  
 4.2 Authority. Buyer has all requisite power and authority to execute and deliver this Agreement and to perform, carry out and consummate the
transactions contemplated hereby. The execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of Buyer. This Agreement constitutes the legal, valid and binding obligation of
Buyer, enforceable it in accordance with its terms. 
  
 4.3 No
Breach. Neither the execution and delivery of this Agreement by Buyer nor the consummation of the transactions contemplated herein will: (i) violate any provision of the Certificate of Incorporation or By-laws of Buyer, (ii) conflict
with, result in a breach of or constitute a default (or an event which, with or without notice, lapse of time or both, would constitute a default) under, or give any third party the right to terminate or modify, any material agreement or other
instrument to which Buyer is a party or by Buyer or any of its assets are subject or bound; (iii) conflict with, violate, result in a breach of or constitute a default under any judgment, decree, order or process of any court or governmental
authority applicable to Buyer; (iv) conflict with or violate any material statute, law or regulation applicable to Buyer’s business; and (v) no event has occurred or with the passage of time or the giving of notice will occur which
would prevent Buyer from obtaining any authorization, consent, approval or waiver from any federal or state governmental or regulatory authority required in connection with the manufacture or sale of the Products in the Territory. 
  
 4.4 Buyer takes full responsibility for post-marketing reporting of adverse
drug experiences in accordance with 21 CFR 314.80. 

 ARTICLE IV 
  

INDEMNIFICATION 
  
 7.1 Indemnification by Seller. Seller shall indemnify and hold Buyer and its Affiliates, and their respective directors, officers, employees,
agents and representatives and all of their successors and assigns (collectively “Buyer Claimants” and individually a “Buyer Claimant”) harmless from and defend each of them from and against any and all demands, claims, actions,
liabilities, losses, costs damages or expenses whatsoever (including any reasonable attorneys’ fees) (collectively, “Losses”) asserted against, imposed upon or incurred by the Buyer Claimants resulting from or arising out of
(a) any breach of any representation or warranty of Seller contained herein; (b) any breach of any covenant or obligation of Seller contained herein; (c) any claim, indebtedness, liability or obligation to third parties resulting from
or arising out of Seller’s ownership of the Included Assets prior to the Transfer Date; and (d) any claim related to the Excluded Liabilities. 
  
 7.2 Indemnification by Buyer. Buyer shall indemnify and save Seller and its Affiliates, and their respective directors, officers, employees, agents
and representatives (collectively “Seller Claimants” and individually a “Seller Claimant”) harmless from and defend each of them from and against any and all Losses asserted against, imposed upon or incurred by the Seller
Claimants resulting from or arising out of (a) any breach of any representation or warranty of Buyer contained herein; (b) any breach of any covenant or obligation of Buyer contained herein; (c) any claim, indebtedness, liability or
obligation to third parties resulting from or arising out of Buyer’s ownership of the Included Assets. 
  
 7.3 Limitations. 
  
 (a) IN NO EVENT SHALL EITHER PARTY HERETO BE RESPONSIBLE OR LIABLE FOR CONSEQUENTIAL, INCIDENTAL OR OTHER INDIRECT DAMAGES OF ANY KIND
(WHETHER ARISING UNDER CONTRACT, TORT, OR OTHERWISE) INCLUDING, BUT NOT LIMITED TO, LOST PROFITS OR LOSS OF BUSINESS OPPORTUNITY, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IN NO EVENT SHALL ANY PARTY HERETO BE LIABLE FOR ANY PUNITIVE OR
EXEMPLARY DAMAGES. 
  
 The indemnification rights of the parties under this
Agreement are the sole and exclusive rights and remedies of the parties hereunder for money damages. 

 ARTICLE VIII 
  
 MISCELLANEOUS 
  
 8.1 Expenses. Each party hereto shall pay its own expenses incurred in connection with this Agreement. All transfer taxes applicable to the
conveyance and transfer from Seller to Buyer of the Included Assets and any other transfer or documentary taxes or any filing or recording fees applicable to such conveyance shall be paid by the party upon whom primary burden for payment is placed
by applicable law. Each party shall use reasonable efforts to avail itself of any available exemptions from any such taxes or fees, and to cooperate with the other party in providing any information and documentation that may be necessary to obtain
such exemptions. 
  
 8.2 Amendment. This Agreement may not
be terminated, amended, altered or supplemented except by a written agreement executed by the parties hereto. 
  
 8.3 Entire Agreement. This Agreement, including the schedules and exhibits hereto, the instruments and other documents delivered pursuant to this
Agreement contains the entire agreement of the parties relating to the subject matter of this Agreement and supersede all prior agreements and understandings of any kind between the parties respecting such subject matter. 
  
 8.4 Further Assurances. Buyer and Seller shall, and shall, if
applicable, cause their respective Affiliates to, at the request of the other, execute and deliver such other instruments of conveyance and transfer and assumption and take such other action as may be reasonably requested so as to consummate the
transactions contemplated hereby of otherwise to consummate the intent of this Agreement. 
  
 8.5 Notices. All notices, consents, directions, approvals, instructions, requests and other communications required or permitted by the terms of this Agreement to be given to any Person shall be in writing, and
any such communication shall become effective five business days after being deposited in the mail, certified or registered, with appropriate postage prepaid for first class mail, or, if delivered by hand or courier service, when received (if
received during normal business hours on a business day, or if not, then on the next business day), and shall be directed to the following address: 

									
	 	 	If to Buyer:	 	 	 	 
	 	 	 	 	 AMERICAN ANTIBIOTICS, LLC
 6950 Bryan Dairy Road
 Largo, Florida 33777
 USA
 Attention: Dr. Kotha Sekharam, Ph. D., President
	 	 

  
 or to such other address as a party
may have furnished to the other parties in writing in accordance herewith, except that notices of change of address shall only be effective upon receipt. 
  
 8.5 Counterparts. This Agreement may be executed in two or more counterparts, and by the different parties hereto in separate counterparts, each of
which when executed shall be deemed to be an original, but all of which together shall constitute one and the same documents. 
  
 8.6 Governing Law and Arbitration. This agreement and all issues arising hereunder or relating hereto, including, without limitation, its
construction, validity, breach, and damages for breach shall be governed by and construed in accordance with the laws of the State of Maryland (without regard to its conflict of laws principles). Any action, cause of action, or dispute arising under
or relating to this agreement shall be brought only in the courts of the state of Maryland or the federal court of the United States and each of the Parties expressly consents to personal jurisdiction in the State of Maryland with respect to such
action, cause of action, or dispute. 
  
 8.7 Binding
Effect. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns. 
  
 8.8 Severability. Any provision of this Agreement that shall be prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be
ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions thereof and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in
any other jurisdiction. To the extent permitted by applicable law, the parties to such instrument waive any provision of law that renders any provision thereof prohibited or unenforceable in any respect. 
  
 8.9 Headings. The headings contained in this Agreement (including the
exhibits and schedules) are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. 

 8.10 No Agency. Neither party hereto shall be deemed hereunder to be an agent of, or partner or
joint venture with, the other party hereto. 
  
 8.11 Third
Parties. Nothing herein is intended or shall be construed to confer upon or give to any person other than the parties hereto any rights or remedies under or by reason of this Agreement. 
  
 8.12 Exhibits and Schedules. All exhibits and schedules which are
attached to this Agreement are hereby incorporated in this Agreement as though fully set forth at the respective points indicated in this Agreement. Inclusion of information in the schedules shall not be construed as an admission that such
information is material to the business. When a reference is made in this Agreement to a specific schedule, such reference shall be deemed to include, to the extent applicable, all other schedules, to the extent the disclosure on that schedule
provides full and fair notice of the matter disclosed. 
  
 IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written. 
  

			
	AMERICAN ANTIBIOTICS, LLC
		
	By:	 	 /s/ Jugal K. Taneja

	 	 	 Jugal K. Taneja, Managing Member

	 	 	 
	CONSOLIDATED PHARMACEUTICALS GROUP, INC.
		
	By:	 	 /s/ M.T. Turgut

	 	 	 M.T. Turgut

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}]]